. .
Bruker Daltonics
Bruker

Classification of HER2 Receptor Status in Breast Cancer Tissues by MALDI Imaging Mass Spectrometry

Type: Application

Poster

Clinical Proteomics, Expression Proteomics

Number: Technology

DGMS 2010

MALDI-TOF

Year Products

2010

ultraflex III

  Author
 

Sandra Rauser (1); Claudio Marquardt (1); Benjamin Balluff (1,2); Christian Albers (3); Eckhard Belau (3); Ralf Hartmer (3); Detlev Suckau (3); Katja Specht (4); Matthias P Ebert (2); Manfred Schmitt (5); Michaela Aubele (1); Heinz Höfler (1); Ulrike Anders (3); Axel Walch (1) (1) Institute of Pathology, Helmholtz Zentrum München, Neuherberg; (2) Department of Medicine II, Klinikum rechts der Isar, Munich; (3) Bruker Daltonik GmbH, Bremen; (4) Institute of Pathology, TUM, Munich; (5) Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Munich

  Reference
 

DGMS

 

Abstract

 

A new 8.4 kDa biomarker candidate for HER2-positive breast cancer, the cytosolic protein CRIP1 was established by High Definition MALDI Imaging and Top-Down protein ID using ETD/PTR on an ion trap.

 

Related Products

 

 

Download

 

Register with us
In order to get access to all our multimedia specials, additional content and to subscribe to our informative Daltonics E-Dispatch newsletter, please register to our website.